Revvity (RVTY) News Today

Revvity, Inc. (NYSE: RVTY) shares were under pressure as investors weighed a new UBS “Neutral” rating against modestly higher earnings estimates and the company’s planned acquisition of Human Cell Design. The stock’s elevated valuation—approximately 59 times earnings—may make the downgrade more influential, despite UBS raising its price target.

• Positive Sentiment: Revvity agreed to acquire France-based Human Cell Design, adding human pancreatic beta-cell models to its Life Sciences portfolio. The deal could strengthen Revvity’s drug-discovery and preclinical research offerings in diabetes, obesity and other metabolic diseases. Financial terms were not disclosed. Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery
• Positive Sentiment: Zacks Research made small upward revisions to its Revvity EPS forecasts, lifting estimates to $1.28 for third-quarter 2026, $1.65 for fourth-quarter 2026, $1.45 for third-quarter 2027 and $1.66 for second-quarter 2028. The changes provide a modestly supportive signal for future earnings, although Zacks maintained a “Hold” rating.
• Neutral Sentiment: Revvity presented at the Wells Fargo 21st Annual Healthcare Conference. The transcript gives investors additional management commentary, but no specific new financial guidance or immediately market-moving development was identified in the provided information. Revvity Wells Fargo Healthcare Conference Transcript
• Negative Sentiment: UBS initiated coverage with a “Neutral” rating, downgrading the shares from “Buy.” Although it raised its price target to $140 from $120, the more cautious rating signals limited conviction after the stock’s strong advance and could weigh on sentiment. UBS Downgrades Revvity to Neutral From Buy